EFFAT ALEMZADEH¹, LEILA ALLAHQOLI², AFROOZ MAZIDIMORADI³, ESMAT ALEMZADEH^1,4, FAHIMEH GHASEMI^4,5, HAMID SALEHINIYA⁶, IBRAHIM ALKATOUT^7,*

Oncology Research, Vol.32, No.5, pp. 831-847, 2024, DOI:10.32604/or.2024.031006 - 23 April 2024

Abstract Ovarian cancer is among the most lethal gynecological cancers, primarily due to the lack of specific symptoms leading to an advanced-stage diagnosis and resistance to chemotherapy. Drug resistance (DR) poses the most significant challenge in treating patients with existing drugs. The Food and Drug Administration (FDA) has recently approved three new therapeutic drugs, including two poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and niraparib) and one vascular endothelial growth factor (VEGF) inhibitor (bevacizumab) for maintenance therapy. However, resistance to these new drugs has emerged. Therefore, understanding the mechanisms of DR and exploring new approaches to overcome More >

CHIWEN BU^1,2, LIGANG ZHAO¹, LISHAN WANG¹, ZEQIAN YU¹, JIAHUA ZHOU^1,*

Oncology Research, Vol.31, No.4, pp. 495-503, 2023, DOI:10.32604/or.2023.029309 - 25 June 2023

Abstract Pancreatic cancer is one of the most aggressive cancers with a median survival time of less than 5 months, and conventional chemotherapeutics are the main treatment strategy. Poly(ADP-ribose) polymerase (PARP) inhibitors have been recently approved for BRCA1/2-mutant pancreatic cancer, opening a new era for targeted therapy for this disease. However, most pancreatic cancer patients carry wild-type BRCA1/2 with resistance to PARP inhibitors. Here, we reported that mammalian target of rapamycin complex 2 (mTORC2) kinase is overexpressed in pancreatic cancer tissues and promotes pancreatic cancer cell growth and invasion. Moreover, we found that knockdown of the More > Graphic Abstract

DHANYA K. NAMBIAR¹, DEEPALI MISHRA², RANA P. SINGH^2,3,*

Oncology Research, Vol.31, No.4, pp. 405-421, 2023, DOI:10.32604/or.2023.028310 - 25 June 2023

Abstract Ionizing radiation is frequently used to treat solid tumors, as it causes DNA damage and kill cancer cells. However, damaged DNA is repaired involving poly-(ADP-ribose) polymerase-1 (PARP-1) causing resistance to radiation therapy. Thus, PARP-1 represents an important target in multiple cancer types, including prostate cancer. PARP is a nuclear enzyme essential for single-strand DNA breaks repair. Inhibiting PARP-1 is lethal in a wide range of cancer cells that lack the homologous recombination repair (HR) pathway. This article provides a concise and simplified overview of the development of PARP inhibitors in the laboratory and their clinical More > Graphic Abstract

AHMED M. ELSHAZLY^1,2, TUONG VI V. NGUYEN¹, DAVID A. GEWIRTZ^1,*

Oncology Research, Vol.30, No.1, pp. 1-12, 2022, DOI:10.32604/or.2022.026459 - 06 December 2022

Abstract PARP inhibitors have proven to be effective in conjunction with conventional therapeutics in the treatment of various solid as well as hematologic malignancies, particularly when the tumors are deficient in DNA repair pathways. However, as the case with other chemotherapeutic agents, their effectiveness is often compromised by the development of resistance. PARP inhibitors have consistently been reported to promote autophagy, a process that maintains cellular homeostasis and acts as an energy source by the degradation and reutilization of damaged subcellular organelles and proteins. Autophagy can exhibit different functional properties, the most prominent being cytoprotective. In More >

Enrico Mini^*, Ida Landini^*, Laura Lucarini^†, Andrea Lapucci^*, Cristina Napoli^‡, Gabriele Perrone^*, Renato Tassi^*, Emanuela Masini^†, Flavio Moroni^†, Stefania Nobili^‡

Oncology Research, Vol.26, No.2, pp. 333-334, 2018, DOI:10.3727/096504018X15187172557369

Abstract The poly(ADP-ribose) polymerase (PARP) enzymes play a key role in the regulation of cellular processes (e.g., DNA damage repair, genomic stability). It has been shown that PARP inhibitors (PARPIs) are selectively cytotoxic against cells having dysfunctions in genes involved in DNA repair mechanisms (synthetic lethality). Drug-induced PARP inhibition potentiates the activity of anticancer drugs such as 5-fluorouracil in enhancing DNA damage, whose repair involves PARP-1 activity. The aim of this study was to evaluate the inhibitory effects of a novel PARPI, HYDAMTIQ, on growth in human tumor cell lines characterized by different features with regard… More >

Enrico Mini^*, Ida Landini^*, Laura Lucarini^†, Andrea Lapucci^*, Cristina Napoli^‡, Gabriele Perrone^*, Renato Tassi^*, Emanuela Masini^†, Flavio Moroni^†, Stefania Nobili^‡

Oncology Research, Vol.25, No.9, pp. 1441-1451, 2017, DOI:10.3727/096504017X14926854178616

Abstract The poly(ADP-ribose) polymerase (PARP) enzymes play a key role in the regulation of cellular processes (e.g., DNA damage repair, genomic stability). It has been shown that PARP inhibitors (PARPIs) are selectively cytotoxic against cells having dysfunctions in genes involved in DNA repair mechanisms (synthetic lethality). Drug-induced PARP inhibition potentiates the activity of anticancer drugs such as 5-fluorouracil in enhancing DNA damage, whose repair involves PARP-1 activity. The aim of this study was to evaluate the inhibitory effects of a novel PARPI, HYDAMTIQ, on growth in human tumor cell lines characterized by different features with regard… More >